FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945290480> ?p ?o ?g. }

• W2945290480 endingPage "2114" @default.
• W2945290480 startingPage "2107" @default.
• W2945290480 abstract "Abstract Aims To assess the effectiveness and safety of rivaroxaban versus warfarin for the prevention of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with type 2 diabetes (T2D) and non‐valvular atrial fibrillation (NVAF). Materials and methods Using MarketScan data from January 2012 to December 2017, we identified oral anticoagulant‐naïve patients with NVAF and comorbid T2D and ≥12 months of insurance coverage prior to rivaroxaban or warfarin initiation. Differences in baseline covariates between cohorts were adjusted for using inverse probability of treatment weights based on propensity scores (absolute standardized differences <0.1 achieved for all covariates after adjustment). Patients were followed until a MACE, MALE or major bleeding event, oral anticoagulant discontinuation/switch, insurance disenrolment or end of data availability. Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing the cohorts were calculated using Cox regression. Results We identified 10 700 rivaroxaban users (24.1% received a reduced dose) and 13 946 warfarin users. The median (25%, 75% range) age was 70 (62, 79) years, CHA2DS2‐VASc score was 4 (3, 5) and duration of available follow‐up was 1.4 (0.6, 2.7) years. Eleven percent of patients had peripheral artery disease, 5.1% had coronary artery disease, and 5.1% had a prior MALE, at baseline. Rivaroxaban was associated with a 25% (95% CI 4‐41) reduced risk of MACE and a 63% (95% CI 35–79) reduced risk of MALE compared to warfarin. Major bleeding risk did not significantly differ between cohorts (HR 0.95). Conclusions Among patients with NVAF and T2D treated in routine practice, rivaroxaban was associated with lower risks of both MACE and MALE versus warfarin, with no significant difference in major bleeding." @default.
• W2945290480 created "2019-05-29" @default.
• W2945290480 creator A5004003194 @default.
• W2945290480 creator A5005652290 @default.
• W2945290480 creator A5009397280 @default.
• W2945290480 creator A5034742104 @default.
• W2945290480 creator A5045621916 @default.
• W2945290480 creator A5061173220 @default.
• W2945290480 creator A5074035842 @default.
• W2945290480 date "2019-06-11" @default.
• W2945290480 modified "2023-10-06" @default.
• W2945290480 title "Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and type 2 diabetes" @default.
• W2945290480 cites W1551095964 @default.
• W2945290480 cites W2036193982 @default.
• W2945290480 cites W2048470090 @default.
• W2945290480 cites W2079491969 @default.
• W2945290480 cites W2116325340 @default.
• W2945290480 cites W2163278718 @default.
• W2945290480 cites W2612251907 @default.
• W2945290480 cites W2749380187 @default.
• W2945290480 cites W2793659838 @default.
• W2945290480 cites W2801261887 @default.
• W2945290480 cites W2803941320 @default.
• W2945290480 cites W2807860129 @default.
• W2945290480 cites W2897413286 @default.
• W2945290480 cites W3004050106 @default.
• W2945290480 cites W4205645630 @default.
• W2945290480 cites W4214932376 @default.
• W2945290480 cites W4229536675 @default.
• W2945290480 doi "https://doi.org/10.1111/dom.13787" @default.
• W2945290480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31099460" @default.
• W2945290480 hasPublicationYear "2019" @default.
• W2945290480 type Work @default.
• W2945290480 sameAs 2945290480 @default.
• W2945290480 citedByCount "26" @default.
• W2945290480 countsByYear W29452904802019 @default.
• W2945290480 countsByYear W29452904802020 @default.
• W2945290480 countsByYear W29452904802021 @default.
• W2945290480 countsByYear W29452904802022 @default.
• W2945290480 countsByYear W29452904802023 @default.
• W2945290480 crossrefType "journal-article" @default.
• W2945290480 hasAuthorship W2945290480A5004003194 @default.
• W2945290480 hasAuthorship W2945290480A5005652290 @default.
• W2945290480 hasAuthorship W2945290480A5009397280 @default.
• W2945290480 hasAuthorship W2945290480A5034742104 @default.
• W2945290480 hasAuthorship W2945290480A5045621916 @default.
• W2945290480 hasAuthorship W2945290480A5061173220 @default.
• W2945290480 hasAuthorship W2945290480A5074035842 @default.
• W2945290480 hasConcept C126322002 @default.
• W2945290480 hasConcept C164705383 @default.
• W2945290480 hasConcept C197934379 @default.
• W2945290480 hasConcept C207103383 @default.
• W2945290480 hasConcept C2776301958 @default.
• W2945290480 hasConcept C2778213512 @default.
• W2945290480 hasConcept C2778661090 @default.
• W2945290480 hasConcept C2778715236 @default.
• W2945290480 hasConcept C2779161974 @default.
• W2945290480 hasConcept C2780400711 @default.
• W2945290480 hasConcept C2780739214 @default.
• W2945290480 hasConcept C44249647 @default.
• W2945290480 hasConcept C500558357 @default.
• W2945290480 hasConcept C50382708 @default.
• W2945290480 hasConcept C71924100 @default.
• W2945290480 hasConceptScore W2945290480C126322002 @default.
• W2945290480 hasConceptScore W2945290480C164705383 @default.
• W2945290480 hasConceptScore W2945290480C197934379 @default.
• W2945290480 hasConceptScore W2945290480C207103383 @default.
• W2945290480 hasConceptScore W2945290480C2776301958 @default.
• W2945290480 hasConceptScore W2945290480C2778213512 @default.
• W2945290480 hasConceptScore W2945290480C2778661090 @default.
• W2945290480 hasConceptScore W2945290480C2778715236 @default.
• W2945290480 hasConceptScore W2945290480C2779161974 @default.
• W2945290480 hasConceptScore W2945290480C2780400711 @default.
• W2945290480 hasConceptScore W2945290480C2780739214 @default.
• W2945290480 hasConceptScore W2945290480C44249647 @default.
• W2945290480 hasConceptScore W2945290480C500558357 @default.
• W2945290480 hasConceptScore W2945290480C50382708 @default.
• W2945290480 hasConceptScore W2945290480C71924100 @default.
• W2945290480 hasFunder F4320307771 @default.
• W2945290480 hasIssue "9" @default.
• W2945290480 hasLocation W29452904801 @default.
• W2945290480 hasLocation W29452904802 @default.
• W2945290480 hasOpenAccess W2945290480 @default.
• W2945290480 hasPrimaryLocation W29452904801 @default.
• W2945290480 hasRelatedWork W19155525 @default.
• W2945290480 hasRelatedWork W2106143461 @default.
• W2945290480 hasRelatedWork W2152794849 @default.
• W2945290480 hasRelatedWork W2402724319 @default.
• W2945290480 hasRelatedWork W2606162097 @default.
• W2945290480 hasRelatedWork W2801261887 @default.
• W2945290480 hasRelatedWork W2807517899 @default.
• W2945290480 hasRelatedWork W2920404400 @default.
• W2945290480 hasRelatedWork W2981470879 @default.
• W2945290480 hasRelatedWork W4212819218 @default.
• W2945290480 hasVolume "21" @default.
• W2945290480 isParatext "false" @default.
• W2945290480 isRetracted "false" @default.
• W2945290480 magId "2945290480" @default.

• next